C
Corey J. Langer
Researcher at Fox Chase Cancer Center
Publications - 207
Citations - 18518
Corey J. Langer is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 47, co-authored 171 publications receiving 17546 citations. Previous affiliations of Corey J. Langer include University of Pittsburgh & Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Joan H. Schiller,David P. Harrington,Chandra P. Belani,Corey J. Langer,Alan B. Sandler,James E. Krook,Junming Zhu,David H. Johnson +7 more
TL;DR: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer.
Journal ArticleDOI
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti,A. Dimitrios Colevas,Ann Setser,Valerie W. Rusch,David P. Jaques,Volker Budach,Corey J. Langer,Barbara A. Murphy,Richard Cumberlin,C. Norman Coleman,Philip Rubin +10 more
TL;DR: Recent progress in the evolution of adverse effects grading systems is updated and the development of CTCAE v3.0 is reviewed, which represents an international collaboration and consensus of the oncology research community.
Journal ArticleDOI
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
David H. Johnson,Louis Fehrenbacher,William Novotny,Roy S. Herbst,John Nemunaitis,David M. Jablons,Corey J. Langer,Russell F. DeVore,Jacques Gaudreault,Lisa A. Damico,Eric Holmgren,Fairooz F. Kabbinavar +11 more
TL;DR: Bvacizumab in combination with carboplatin and paclitaxel improved overall response and time to progression in patients with advanced or recurrent non-small-cell lung cancer.
Journal ArticleDOI
Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival
Henry T. Hoffman,Kimberly R. Porter,Lucy Hynds Karnell,Jay S. Cooper,Randall S. Weber,Corey J. Langer,K. Kian Ang,Andrew K. Stewart,Robert A. Robinson +8 more
TL;DR: This data indicates that the survival among patients with laryngeal cancer during the past 2 decades in the United States has decreased, but there has been an increase in the nonsurgical treatment of larynGEal cancer.
Journal ArticleDOI
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.
Corey J. Langer,Judith Manola,Patricia Bernardo,John W. Kugler,Philip Bonomi,David Cella,David H. Johnson +6 more
TL;DR: Responsibility rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients, although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity.